Eagle Pharmaceuticals Inc (EGRX) SEC filings

Eagle Pharmaceuticals Inc (EGRX) SEC filings — 10-K, 10-Q, 8-K, and Form 4 as cached from EDGAR. When an exhibit lands, this page shows the headline, the numbers, and why it matters.

Those exhibit numbers sit next to the income-statement cache: Latest reported EGRX revenue for 2022-12-31 was $316.6M. Net income was $35.6M. Revenue was up 84.6% from 2021-12-31 to 2022-12-31. EGRX currently screens at market cap $3.3M. The EGRX filings page is the source view; the stock page is the research view.

EDGAR remains the official archive. Lician caches 8-K exhibits so you can read what Eagle Pharmaceuticals Inc said without waiting on a live EDGAR scrape. Item 2.02 is the earnings exhibit — this page prefers EX-99.1 revenue, growth, EPS, and guidance over a form-type label. Form 4 insider prints stay on the same ticker timeline.